Durata Therapeutics, Inc.
Period Ending Dec 31, 2013 Dec 31, 2012 Dec 31, 2011 Dec 31, 2010
Total Revenue - - - -
Cost of Revenue - - - -
Gross Profit - - - -
Operating Expenses
Research and Development 37,317 51,695 30,133 4,818
Sales, General and Admin. 18,602 9,788 4,305 2,777
Non-Recurring Items 1,053 1,097 1,121 6,300
Other - - - -
Operating Income (56,972) (62,580) (35,559) (13,895)
Income From Continuing Operations
Add'l Income/Expense Items (1,665) 41 15 3
Earnings Before Interest and Tax (58,637) (62,539) (35,544) (13,892)
Interest Expense 2,226 - - -
Earnings Before Tax (60,863) (62,539) (35,544) (13,892)
Income Tax 1,278 - (2,511) (2,878)
Minority Interest - - - -
Equity Earnings Unconsolidated Subsidiary - - - -
Net Income Cont. Operations (64,369) (62,539) (33,033) (11,014)
Non Recurring Events
Discontinued Operations - - - -
Extraordinary Items - - - -
Effect of Accounting Changes - - - -
Other Items - - - -
Net Income (62,141) (62,539) (33,033) (11,014)
Preferred Stock and Other Adjustments - - - -
Net Income Applicable to Common Shareholders (62,141) (62,539) (33,033) (11,014)